Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics

Starting soon

Conditions studied: Multiple Myeloma (MM), Smoldering Multiple Myeloma (SMM), MGUS

In brief

Study on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics features, to effectively distinguish myeloma patients from healthy individuals.

Key facts

Study ID

NCT07684274

Run by

The First Affiliated Hospital with Nanjing Medical University

People needed

290

Starts

2026-06-13

Expected to finish

2027-12-31

Last updated by the study team

2026-07-06

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age over 40 years.
• Diagnosed with MM, SMM, or MGUS through standard diagnostic procedures.
• Voluntarily participating and signed written informed consent.

You may not qualify if…

• Pregnant or lactating women.
• Prior cancer diagnosis within the past 5 years, or history of any form of systemic cancer therapy (including chemotherapy, targeted therapy, immunotherapy, etc.).
• History of organ transplantation, or allogeneic bone marrow or stem cell transplantation.
• History of blood transfusion within 7 days prior to blood collection.
• Poor compliance or potential interference with signing informed consent as judged by the investigator, or any other conditions rendering the subject unsuitable for the study.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.